PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :		(11) International Publication Number: WO 93/14076
C07D 295/12, A61K 31/495	A1	(43) International Publication Date: 22 July 1993 (22.07.93)

(21) International Application Number: PCT/GB92/02399

(22) International Filing Date: 24 December 1992 (24.12.92)

(30) Priority data:
9200293.0 8 January 1992 (08.01.92) GB

(71) Applicant *(for all designated States except US):* JOHN WYETH & BROTHER LIMITED [GB/GB]; Huntercombe Lane South, Taplow, Maidenhead, Berkshire SL6 0PH (GB).

(72) Inventor; and
(75) Inventor/Applicant *(for US only) :* CLIFFE, Ian, Anthony [GB/GB]; Priory View, One Pin Lane, Farnham Common, Bucks SL2 3RA (GB).

(74) Agents: BROWN, Keith, John, Symons et al.; Wyeth Laboratories, Huntercombe Lane South, Taplow, Maidenhead, Berkshire SL6 0PH (GB).

(81) Designated States: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).

Published
With international search report.

(54) Title: PIPERAZINE DERIVATIVES AS 5-HT RECEPTORS ANTAGONISTS



(I)

(57) Abstract

Compounds of formula (I) where A is an alkylene chain of 2 to 5 carbon atoms optionally substituted by one or more lower alkyl groups, R represents hydrogen or one or two same or different lower alkyl groups, R^1 is a monocyclic aryl or heteroaryl radical, R^2 is a mono or bicycle aryl radical and R^3 is cycloalkyl and the pharmaceutically acceptable acid addition salts are novel. They are 5-HT_{1A}-antagonists which may be used, for example, in treating anxiety.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo			SE	Sweden
CH	Switzerland	KR	Republic of Korea	SK	Slovak Republic
CI	Côte d'Ivoire	KZ	Kazakhstan	SN	Senegal
CM	Cameroon	LI	Liechtenstein	SU	Soviet Union
CS	Czechoslovakia	LK	Sri Lanka	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	UA	Ukraine
DK	Denmark	MG	Madagascar	US	United States of America
ES	Spain	ML	Mali	VN	Viet Nam
FI	Finland	MN	Mongolia		

PIPERAZINE DERIVATIVES AS 5-HT RECEPTORS ANTAGONISTS

This invention relates to piperazine derivatives, to processes for their preparation, to their use and to pharmaceutical compositions containing them. The novel compounds act on the central nervous system by binding to 5-HT receptors (as more fully explained below) and hence can be used as medicaments for treating humans and other mammals.

The novel compounds of the invention are those of the general formula



(I)

and the pharmaceutically acceptable acid addition salts thereof.

In formula (I)

A is an alkylene chain of 2 to 5 carbon atoms optionally substituted by one or more lower alkyl groups,

R represents hydrogen or one or two same or different lower alkyl groups,

R^1 is a monocyclic aryl or heteroaryl radical,

R^2 is a mono or bicyclic aryl radical

and R^3 is cycloalkyl.

The term "lower" as used herein means that the radical referred to contains 1 to 6 carbon atoms. Preferably such radicals contain 1 to 4 carbon atoms. Examples of "lower alkyl" radicals are methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl and isopentyl.

A cycloalkyl group can contain 3 to 12 carbon atoms. Preferably a cycloalkyl group is cyclopentyl, cyclohexyl or cycloheptyl, most preferably cyclohexyl. Cycloalkyl groups also include bicyclic, tricyclic and tetracyclic groups, eg adamantyl.

When used herein "a monocyclic aryl radical" means a phenyl radical which optionally may be substituted by one or more substituents and "a mono or bicyclic aryl radical" means an aromatic radical having 6 to 12 carbon atoms (eg phenyl or naphthyl) which optionally may be substituted by one or more substituents. Preferred substituents are lower alkyl, lower alkoxy (eg methoxy, ethoxy, propoxy, butoxy), halogen, halo(lower)alkyl (eg trifluoromethyl), nitro, nitrile, amido, (lower)alkoxycarbonyl, amino, (lower)alkylamino or di(lower)alkylamino substituents.

Preferably R^1 is a phenyl radical containing a substituent in the ortho position. A particularly preferred example of R^1 is o-(lower)alkoxyphenyl eg o-methoxyphenyl.

Preferably R^2 is an optionally substituted phenyl radical.

The term "monocyclic heteroaryl radical" refers to a monocyclic aromatic radical containing one or more

hetero atoms (eg oxygen, nitrogen, sulphur) and which may be optionally substituted by one or more substituents. Examples of suitable substituents are given above in connection with "aryl" radicals. Preferably the monocyclic heteroaryl radical contains 5 to 7 ring atoms. Preferably the hetero ring contains a nitrogen hetero atom with or without one or more further hetero atoms. When R^1 is a heteroaryl radical it is preferably an optionally substituted pyrimidyl (particularly 2-pyrimidyl) radical.

Preferred compounds have the following substituents either independently or in combination:-

(a) A is $-(CH_2)_2-$, $-(CH_2)_3-$ or $-(CH_2)_4-$

(b) R is hydrogen

(c) R^1 is o-methoxyphenyl

(d) R^2 is phenyl

(e) R^3 is cyclohexyl

The compounds of the invention may be prepared by methods known in the art from known starting materials or starting materials that may be prepared by conventional methods.

One method of preparing the compounds of the invention comprises acylating an amine of formula



(II)

(where A, R, R^1 and R^2 have the meanings given above) with an acid of formula

$$R^3COOH \qquad \text{(III)}$$

(where R^3 is as defined above) or with an acylating derivative thereof. Examples of acylating derivatives include the acid halides (eg acid chlorides) azides, anhydrides, imidazolides (eg obtained from carbonyldiimidazole), activated esters or O-acyl ureas obtained from a carbodiimide such as a dialkylcarbodiimide particularly cyclohexylcarbodiimide.

The starting amine of formula (II) may be prepared by a process such as that exemplified below:



(where R, R^1, R^2 and A are as defined above, Hal is halo, particularly chloro or bromo and A' is an alkylene chain of 1 to 3 carbon atoms optionally substituted by one or more lower alkyl groups). The reduction may be carried out with, for example, a boron reducing agent eg borane-dimethyl sulphide.

A second method of preparing the compounds of the invention comprises alkylating an amide of formula (IV)



(IV)

with an alkylating agent providing the group



The alkylating agent may be, for example, a compound of formula



where A, R and R^1 are as defined above and X is a leaving group such as halogen or an alkyl - or aryl-sulphonyloxy group.

A third method of preparing the compounds of the invention comprises alkylating a compound of formula



with a compound of formula

$$X\text{-}A\text{—}NR^2.CO.R^3 \qquad (V)$$

(where A, R, R^1,R^2 and R^3 and X are as defined above). The starting compound of formula (V) may, for example, be prepared as exemplified below

$$X\text{-}A\text{-}Br + NHR^2COR^3 \longrightarrow (V)$$

Where R^1 is a group that is activated towards nucleophilic substitution the compounds of the invention may be prepared by a further method which comprises reacting the appropriate fluoro compound of formula R^1F with a piperazine compound of formula



The processes described above may be carried out to give a compound of the invention in the form of a free base or as an acid addition salt. If the compound of the invention is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid addition salt. Conversely, if the product of the process is a free base an acid addition salt, particularly a pharmaceutically acceptable acid addition salt, may be obtained by dissolving the free

base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds.

Examples of acid addition salts are those formed from inorganic and organic acids, such as sulphuric, hydrochloric, hydrobromic, phosphoric, tartaric, fumaric, maleic, citric, acetic, formic, methanesulphonic, p-toluenesulphonic, oxalic and succinic acids.

The compounds of the invention may contain one or more asymmetric carbon atoms, so that the compounds can exist in different steroisomeric forms. The compounds can be, for example, racemates or optically active forms. The optically active forms can be obtained by resolution of the racemates or by asymmetric synthesis.

The compounds of the present invention possess pharmacological activity. In particular, they act on the central nervous system by binding to 5-HT receptors. In pharmacological testing it has been shown that the compounds particularly bind to receptors of the 5-HT_{1A} type. In general, the compounds selectively bind to receptors of the 5-HT_{1A} type to a much greater extent than they bind to other receptors such as α_1 and D_2 receptors. Many exhibit activity as 5-HT_{1A} antagonists in pharmacological testing. The compounds of the invention can be used for the treatment of CNS disorders, such as anxiety in mammals, particularly humans. They may also be used as antidepressants, hypotensives, as agents for regulating the sleep/wake cycle, feeding behaviour and/or sexual

function and for treating cognition disorders.

The compounds of the invention were tested for $5\text{-}HT_{1A}$ receptor binding activity in rat hippocampal membrane homogenate by the method of B S Alexander and M D Wood, J Pharm Pharmacol, 1988, 40, 888-891.

The compound of Example 2 which is a representative compound of the invention, had a IC_{50} of 4 nM in this test procedure.

The compounds are tested for $5\text{-}HT_{1A}$ receptor antagonism activity in a test involving the antagonism of 5-carboxamidotryptamine in the guinea-pig ileum in vitro (based upon the procedure of Fozard et al, Br J Pharmac, 1985, 86, 601P). The results for compounds of the invention are given below. The compound of Example 2 had a pA_2 of 8.2.

The invention also provides a pharmaceutical composition comprising a compound or a pharmaceutically acceptable acid addition salt thereof in association with a pharmaceutically acceptable carrier. Any suitable carrier known in the art can be used to prepare the pharmaceutical composition. In such a composition, the carrier is generally a solid or liquid or a mixture of a solid or liquid.

Solid form compositions include powders, granules, tablets, capsules (eg hard and soft gelatine capsules), suppositories and pessaries. A solid carrier can be, for example, one or more substances which may also act as flavouring agents, lubricants, solubilisers,

suspending agents, fillers, glidants, compression aides, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99%, eg from 0.03 to 99%, preferably 1 to 80% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.

The term "composition" is intended to include the formulation of an active ingredient with encapsulating material as carrier to give a capsule in which the active ingredient (with or without other carriers) is surrounded by the carrier, which is thus in association with it. Similarly cachets are included.

Liquid form compositions include, for example, solutions, suspensions, emulsions, syrups, elixirs and pressurised compositions. The active ingredient, for example, can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilisers, emulsifiers, buffers, preservatives, sweeteners, flavouring agents,

suspending agents, thickening agents, colours, viscosity regulators, stabilisers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above, eg cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (eg glycerol and glycols) and their derivatives, and oils (eg fractionated coconut oil and arachis oil). For parenteral administration the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.

Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. When the compound is orally active it can be administered orally either in liquid or solid composition form.

Preferably the pharmaceutical composition is in unit dosage form, eg as tablets or capsules. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged composition, for example packeted powders, vials, ampoules, prefilled syringes or sachets containing liquid. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form. The quantity of the active ingredient in unit dose of composition may be varied or adjusted from 0.5 mg or less to 750 mg or

more, according to the particular need and the activity of the active ingredient.

The following Examples illustrate the invention. Example 1 illustrates the preparation of an intermediate.

Example 1

N-Phenyl cyclohexane carboxamide

Cyclohexanecarbonyl chloride (14.66 g, 0.1 mol) was added dropwise to a stirred solution of aniline hydrochloride (12.96 g 0.1 mol) and N, N-diisopropylethylamine (15.20 g, 0.2 mol) in dichloromethane (100 ml). The solution was stirred under an atmosphere of argon for 18 h, washed with 0.1 N-HCl (3 x 50 ml) and dilute sodium hydrogen carbonate solution (50 ml), dried ($MgSO_4$), and evaporated in vacuo to give the product (18.6 g) as white crystals.

Example 2

N-(2-(4-(2-Methoxyphenyl)piperazin-1-yl)ethyl)-N-phenylcyclohexanecarboxamide

A solution of the product of example 1 (2.03 g, 0.1 mol) in DMF (50 ml) was added dropwise to a suspension of potassium hydride, 35% dispersion in mineral oil (1.2 g, 0.011 mol) in DMF (20 ml). The suspension was stirred for 2 h, treated with 1-(2-chloroethyl)-4-(2-methoxyphenyl)piperazine (2.53 g, 0.01 mol) stirred for 5 h at 80°C, cooled to room temperature, basified with dilute potassium carbonate solution, and evaporated in vacuo. The residue was dissolved in water (200 ml) and the solution extracted with ether (3 x 100 ml). The extracts were washed with water (100 ml), dried ($MgSO_4$), and evaporated in vacuo to give an oil which

was purified by chromatography [silica; ethyl acetate-toluene (1:1)] to give the product (0.41 g) as a yellow oil. Addition of ethereal hydrogen chloride and evaporation gave the dihydrochloride salt of the product as a white solid, m.p. 118-123°C. (Found: C, 62.6; H, 7.8; N, 8.2. $C_{26}H_{35}N_3O_2 \cdot 2HCl.\frac{1}{4}H_2O$ requires C, 62.6; H, 7.6; N, 8.4%).

CLAIMS

1. A compound of the general formula



(I)

or a pharmaceutically acceptable acid addition salt thereof wherein

A is an alkylene chain of 2 to 5 carbon atoms optionally substituted by one or more lower alkyl groups,

R represents hydrogen or one or two same or different lower alkyl groups,

R^1 is a monocyclic aryl or heteroaryl radical,

R^2 is a mono or bicyclic aryl radical

and R^3 is cycloalkyl.

2. A compound as claimed in claim 1 in which A is $-(CH_2)_2-$, $-(CH_2)_3-$ or $-(CH_2)_4-$.

3. A compound as claimed in claim 1 or 2 in which R^1 is o-methoxyphenyl.

4. A compound as claimed in any one of claims 1 to 3 in which R^2 is phenyl.

5. A compound as claimed in any one of claims 1 to 4 in which R^3 is cyclohexyl.

6. A compound as claimed in claim 1 which is N-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)-N-phenylcyclohexanecarboxamide or a pharmaceutically acceptable acid addition salt thereof.

7. A process for preparing a compound claimed in claim 1 which comprises

(a) acylating an amine of formula (II)



(II)

(where A, R, R^1 and R^2 have the meanings defined in claim 1)

with an acid of formula

$$R^3COOH \qquad \text{(III)}$$

(where R^3 is as defined in claim 1) or with an acylating derivative thereof

or

(b) alkylating an amide of formula (IV)

(IV)

(where R^2 and R^3 are as defined in claim 1) with an alkylating agent providing the group



(where A, R and R^1 are as defined in claim 1)

or

(c) alkylating a compound of formula



with a compound of formula

$$X\text{-}A\text{—}NR^2.CO.R^3$$

(where A, R^2 and R^3 are as defined in claim 1 and X is a leaving group)

or

(d) resolving a racemic compound claimed in claim 1 into an enantiomer

or

(e) converting a base claimed in claim 1 into a pharmaceutically acceptable salt or converting a pharmaceutically acceptable salt into the free base.

8. A pharmaceutical composition comprising a compound claimed in claim 1 in association with a

pharmaceutically acceptable carrier.

9. A pharmaceutical composition as claimed in claim 8 in which the compound is prepared by the process claimed in claim 7.

10. A process for preparing a pharmaceutical composition which comprises bringing a compound claimed in claim 1 into association with a pharmaceutically acceptable carrier.

11. A compound as claimed in claim 1 for use as a 5-HT_{1A} antagonist.

12. A compound as claimed in claim 1 for use as an antidepressant, hypotensive, an agent for regulating the sleep/wake cycle, feeding behaviour or sexual function or for treating anxiety or cognition disorders.

INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 92/02399

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)[6]

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 C07D295/12; A61K31/495

II. FIELDS SEARCHED

Minimum Documentation Searched[7]

Classification System	Classification Symbols
Int.Cl. 5	C07D

Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched[8]

III. DOCUMENTS CONSIDERED TO BE RELEVANT[9]

Category[10]	Citation of Document,[11] with indication, where appropriate, of the relevant passages[12]	Relevant to Claim No.[13]
A	US,A,3 037 982 (OTIS E. FANCHER ET. AL.) 5 June 1962 *Complete specification* ---	1-12
A	EP,A,0 015 615 (DUPHAR INTERNATIONAL RESEARCH B. V.) 17 September 1980 *Complete specification* ---	1-12
A	EP,A,0 048 043 (DUPHAR INTERNATIONAL RESEARCH B. V.) 24 March 1982 *Complete specification* ---	1-12
A	EP,A,0 048 045 (DUPHAR INTERNATIONAL RESEARCH B. V.) 24 March 1982 *Complete specification* ---	1-12

-/--

[10] Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report
01 APRIL 1993	19. 04. 93
International Searching Authority	**Signature of Authorized Officer**
EUROPEAN PATENT OFFICE	LUYTEN H.W.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category°	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	EP,A,0 343 961 (AMERICAN HOME PRODUCTS) 29 November 1989 *Complete specification* ---	1-12
P,A	EP,A,0 496 692 (FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS) 29 July 1992 *Complete specification* -----	1-12

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

GB 9202399
SA 68278

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 01/04/93

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US-A-3037982		None		
EP-A-0015615	17-09-80	AT-T-	2219	15-01-83
		AU-B-	532411	29-09-83
		AU-A-	5584880	04-09-80
		CA-A-	1138461	28-12-82
		JP-A-	55141478	05-11-80
		SU-A-	1039442	30-08-83
EP-A-0048043	24-03-82	NL-A-	8005131	01-04-82
EP-A-0048045	24-03-82	NL-A-	8005133	01-04-82
		AU-A-	7502981	18-03-82
		CA-A-	1155116	11-10-83
		JP-A-	57081464	21-05-82
EP-A-0343961	29-11-89	AU-B-	628341	17-09-92
		AU-A-	3502589	30-11-89
		GB-A,B	2218988	29-11-89
		JP-A-	2015059	18-01-90
		US-A-	5010078	23-04-91
		US-A-	5106849	21-04-92
EP-A-0496692	29-07-92	JP-A-	4321677	11-11-92